Pila Pharma (Sweden) Insiders
| PILA Stock | 2.03 0.03 1.46% |
Pila Pharma employs about 3 people. The company is managed by 10 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 0.3 employees per reported executive. Breaking down Pila Pharma's management performance can provide insight into the firm performance.
| Mike Frodsham Insider CTO Pharma |
| Gustav Gram Insider Head Office |
Pila |
Pila Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2713) % which means that it has lost $0.2713 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3032) %, meaning that it generated substantial loss on money invested by shareholders. Pila Pharma's management efficiency ratios could be used to measure how well Pila Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Pila Pharma owns a total of 18.41 Million outstanding shares. Pila Pharma has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Pila Pharma Workforce Comparison
Pila Pharma AB is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 199. Pila Pharma claims roughly 3.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Pila Pharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pila Pharma AB Price Series Summation is a cross summation of Pila Pharma price series and its benchmark/peer.
Pila Pharma Notable Stakeholders
A Pila Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pila Pharma often face trade-offs trying to please all of them. Pila Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pila Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mike Frodsham | CTO Pharma | Profile | |
| Gustav Gram | Head Office | Profile | |
| Masoud Alavi | Head Communication | Profile | |
| Elna Astrom | Chief Officer | Profile | |
| Andy Makin | Head Toxicology | Profile | |
| Alison Foster | Head Pharma | Profile | |
| Miguel Lecumberri | Head Affairs | Profile | |
| Maura McArdle | Head Pharma | Profile | |
| Dorte Gram | CEO Founder | Profile | |
| Simon Hamilton | Head Almac | Profile |
About Pila Pharma Management Performance
The success or failure of an entity such as Pila Pharma AB often depends on how effective the management is. Pila Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pila management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pila management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Pila Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pila Pharma AB. Check Pila Pharma's Beneish M Score to see the likelihood of Pila Pharma's management manipulating its earnings.
Pila Pharma Workforce Analysis
Traditionally, organizations such as Pila Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pila Pharma within its industry.Pila Pharma Manpower Efficiency
Return on Pila Pharma Manpower
| Revenue Per Employee | 239.7K | |
| Revenue Per Executive | 71.9K | |
| Net Loss Per Employee | 5.7M | |
| Net Loss Per Executive | 1.7M |
Additional Tools for Pila Stock Analysis
When running Pila Pharma's price analysis, check to measure Pila Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pila Pharma is operating at the current time. Most of Pila Pharma's value examination focuses on studying past and present price action to predict the probability of Pila Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pila Pharma's price. Additionally, you may evaluate how the addition of Pila Pharma to your portfolios can decrease your overall portfolio volatility.